TAIWANJ PHARMACEUTICALS CO., LTD. TaiwanJ Pharmaceuticals Co., Ltd. Share Price
Equities
6549
TW0006549009
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.85 TWD | -1.25% |
|
-4.82% | -19.66% |
| Sales 2022 | 15.36 493.42 1.21K | Sales 2023 | 22.74 730.79 1.8K | Capitalization | 1.11B 35.61B 87.6B |
|---|---|---|---|---|---|
| Net income 2022 | -92M -2.96B -7.27B | Net income 2023 | -6M -193M -474M | EV / Sales 2022 | 48,027,561 x |
| Net cash position 2022 | 58.83M 1.89B 4.65B | Net cash position 2023 | 57.66M 1.85B 4.56B | EV / Sales 2023 | 46,187,297 x |
| P/E ratio 2022 |
-8.61
x | P/E ratio 2023 |
-183
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.61% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.25% | ||
| 1 week | -4.82% | ||
| Current month | -10.23% | ||
| 1 month | -7.78% | ||
| 3 months | -19.39% | ||
| 6 months | -7.06% | ||
| Current year | -19.66% |
1 week
11.45
12.20
1 month
11.4514.05
Current year
11.4516.60
1 year
11.4530.00
3 years
8.5142.10
5 years
5.5142.10
10 years
5.5164.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hung Chang Yuan
CEO | Chief Executive Officer | - | 10/08/16 |
Hsin Hui Chuang
DFI | Director of Finance/CFO | - | - |
Ying Chu Shih
CHM | Chairman | - | 14/09/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Chih Huang
BRD | Director/Board Member | - | 10/09/15 |
Ming Yuan Cheng
BRD | Director/Board Member | - | 29/05/19 |
Hung Chang Yuan
CEO | Chief Executive Officer | - | 10/08/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 11.85 | -1.25% | 115,216 |
| 14/05/24 | 12 | -0.41% | 574,734 |
| 13/05/24 | 12.05 | +0.42% | 153,573 |
| 10/05/24 | 12 | -1.64% | 193,399 |
| 09/05/24 | 12.2 | -2.01% | 102,894 |
End-of-day quote Taipei Exchange, May 14, 2024
More quotes
TaiwanJ Pharmaceuticals Co., Ltd. is a Taiwan-based company principally engaged in the research and development of new drugs. The Company is specialized in early research of new drugs and development of clinical drugs. The Company's products are used for the treatment of chronic liver diseases. The Company is in the development stage and not generating any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.66% | 27.7M | |
| +7.12% | 113B | |
| +11.09% | 106B | |
| +0.70% | 22.27B | |
| -12.26% | 22.22B | |
| -5.61% | 19.43B | |
| -37.85% | 17.87B | |
| -6.00% | 17.24B | |
| +7.76% | 14.29B | |
| +34.89% | 12.52B |
- Stock Market
- Equities
- 6549 Stock
